Marc Yoskowitz

Marc Yoskowitz currently serves as Chief Executive Officer of Evozyne and holds non-executive director positions at Mallinckrodt Pharmaceuticals and Mereo BioPharma, where involvement includes membership in the R&D Committee. Previously, Marc was a non-executive director at Endo, chairing the Compliance Committee and participating in the Nomination and Governance Committee as well as the Product Portfolio Committee. Additional experience includes advisory roles at Broken String Biosciences Ltd, Paragon Biosciences, and Mahana Therapeutics, as well as serving as Chief Strategy Officer and Executive Vice President at Tempus Life Sciences. Prior roles include Senior Vice President at Pfizer and Hospira, overseeing significant strategy and business operations. Educational credentials encompass a JD from Columbia Law School and a BA from Washington University in St. Louis.